NYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis $39.15 -0.04 (-0.11%) Closing price 09/25/2026 03:59 PM EasternExtended Trading$39.25 +0.10 (+0.26%) As of 09/25/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Teva Pharmaceutical Industries Stock (NYSE:TEVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TEVA alerts:Sign Up Key Stats Today's Range$38.93▼$40.2550-Day Range$30.19▼$40.1852-Week Range$18.27▼$40.79Volume3.87 million shsAverage Volume4.91 million shsMarket Capitalization$45.62 billionP/E Ratio65.25Dividend YieldN/APrice Target$43.73Consensus RatingModerate Buy Company Overview Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders. Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms. The company also develops biosimilar medicines and provides pharmaceutical ingredients to support drug manufacturing. Founded in Jerusalem in 1901, Teva has grown into an international pharmaceutical business serving patients and healthcare providers in markets across North America, Europe and other regions worldwide. Richard Francis has served as Teva’s president and chief executive officer since January 2023.AI Generated. May Contain Errors. Read More Teva Pharmaceutical Industries Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreTEVA MarketRank™: Teva Pharmaceutical Industries scored higher than 68% of companies evaluated by MarketBeat, and ranked 258th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialTeva Pharmaceutical Industries has a consensus price target of $43.73, representing about 11.7% upside from its current price of $39.15.Amount of Analyst CoverageTeva Pharmaceutical Industries has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Teva Pharmaceutical Industries' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth53.85% Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 53.85% in the coming year, from $1.95 to $3.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is 65.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is 65.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 276.17.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 3.71. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Teva Pharmaceutical Industries' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.72% of the float of Teva Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 27.35, which indicates bearish sentiment.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently increased by 11,467.47%, indicating that investor sentiment is decreasing significantly. Dividend0.8 / 5Dividend StrengthN/A Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.70% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend. News and Social Media2.2 / 5News Sentiment0.51 News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.Search InterestOnly 7 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,644,285.00 in company stock.Percentage Held by Insiders0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Teva Pharmaceutical Industries' insider trading history. Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Stock News HeadlinesRoberto Mignone Sells 367,600 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) StockSeptember 24, 2026 | americanbankingnews.comForge’s Fierce Pharma Week Delivered a Powerhouse Event with Over 3,500 Pharmaceutical and Biotech Decision-Makers and Innovators, Representing a 21% Increase in Attendees ...September 23, 2026 | finance.yahoo.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.September 28 at 1:00 AM | Banyan Hill Publishing (Ad)Teva Pharmaceutical Industries Ltd: Teva Releases Q3 2026 Aide MemoireSeptember 23, 2026 | finanznachrichten.deTeva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ETSeptember 23, 2026 | finanznachrichten.deTeva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ETSeptember 23, 2026 | finance.yahoo.comTeva Releases Q3 2026 Aide MemoireSeptember 23, 2026 | finance.yahoo.comInsider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $285,236.70 in StockSeptember 23, 2026 | insidertrades.comSee More Headlines TEVA Stock Analysis - Frequently Asked Questions How have TEVA shares performed this year? Teva Pharmaceutical Industries' stock was trading at $31.21 at the beginning of 2026. Since then, TEVA shares have increased by 25.4% and is now trading at $39.1470. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced its quarterly earnings data on Tuesday, June, 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm earned $4.14 billion during the quarter. Teva Pharmaceutical Industries had a trailing twelve-month return on equity of 32.64% and a net margin of 4.08%. Read the conference call transcript. Who are Teva Pharmaceutical Industries' major shareholders? Top institutional investors of Teva Pharmaceutical Industries include Wellington Management Group LLP (0.66%), Assenagon Asset Management S.A. (0.27%), National Pension Service (0.21%) and California State Teachers Retirement System (0.11%). Insiders that own company stock include Richard D Francis, Eric A Hughes, Mark Sabag, Tal Zvi Zaks, Eliyahu Sharon Kalif, Christine Fox, Richard Daniell, Amir Weiss, Matthew Shields, Eric Drape, Brian Savage, Placid Jover, Vikki L Conway and Roberto Mignone. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T). Company Calendar Last Earnings6/30/2026Today9/28/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TEVA's financial health is in the Green zone, according to TradeSmith. TEVA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TEVA CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees33,950Year Founded1901Price Target and Rating Average Price Target for Teva Pharmaceutical Industries$43.73 High Price Target$50.00 Low Price Target$40.00 Potential Upside/Downside+11.7%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.60 Trailing P/E Ratio65.25 Forward P/E Ratio20.08 P/E Growth3.71Net Income$1.41 billion Net Margins4.08% Pretax Margin4.09% Return on Equity32.64% Return on Assets6.34% Debt Debt-to-Equity Ratio1.56 Current Ratio0.88 Quick Ratio0.67 Sales & Book Value Annual Sales$17.26 billion Price / Sales2.64 Cash Flow$3.72 per share Price / Cash Flow10.51 Book Value$6.88 per share Price / Book5.69Miscellaneous Outstanding Shares1,165,300,000Free Float1,159,003,000Market Cap$45.62 billion OptionableOptionable Beta0.87 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSE:TEVA) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
